Article | November 27, 2023

Navigating EU GMP Annex 1 Revisions In The Age Of Innovation And Accountability In Drug Manufacturing

Source: CAI

By Connie Leech

Regulatory compliance Getty Images-1256156511

Adherence to regulatory standards is non-negotiable in the dynamic world of biotechnology, where innovation advances rapidly and patient safety is paramount. The latest regulation that Biotech companies operating in the European Union (EU) must now comply with is Annex 1 of the EU Good Manufacturing Practice (GMP) guidelines. Often hailed as the blueprint for pharmaceutical manufacturing, Annex 1 sets forth the requirements for the manufacture of sterile medicinal products. The FDA actively contributed to shaping this version of Annex 1, so the imminent adoption of this revised framework by the U.S. regulator seems all but inevitable.

Here, we will delve into the revised EU GMP Annex 1, exploring the changes it introduces and highlighting key considerations for biotech firms to maintain compliance. Additionally, we will examine compelling statistics that underscore the repercussions of non-compliance in this ever-evolving landscape. It is imperative that products falling under the biopharmaceutical umbrella, such as mAbs, gene therapies, and vaccines, adhere to Annex 1.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online